OncoResponse
Seattle
About OncoResponse
OncoResponse is an immuno-oncology biotech company that is leveraging its proprietary human antibody platform to discover novel targets and identify fully human monoclonal antibodies as therapeutics for the treatment of cancers. It identifies genuine human antibodies to a variety of high-value targets linked with immunosuppressive myeloid biology. OncoResponse's antibody pipeline is expected to alleviate TME immunosuppression and boost immune activation, turning cold tumors hot.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $130.1M
- Funding stage: Late Stage Venture
- Last round: Grant (May 2023)
- Website: oncoresponse.com
- Phone: +1 206 805 1600
Industries & Categories
Biopharma, Biotechnology, Health Care, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/oncoresponse-62787 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.